NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, announces the successful completion of its acquisition of a majority equity stake in NKMax Co., Ltd. (“NKMax”), a Korean biotechnology company, out of bankruptcy. This acquisition marks a transformative step for NKGen, granting full control over key global manufacturing infrastructure, intellectual property (“IP”), and exclusive commercialization rights, while solidifying the Company’s position as an independent and vertically integrated leader in NK cell therapeutics.
Read the full article: NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition //
Source: https://www.globenewswire.com/news-release/2025/09/09/3146867/0/en/NKGen-Biotech-Inc-Announces-Completion-of-NKMax-Co-Ltd-Acquisition-Gains-Full-Control-of-Global-Manufacturing-and-Intellectual-Property-Assets.html